Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 08/08

20080207873 - Biosynethetic gene cluster for jerangolids: Domains of jerangolid polyketide synthase and modification enzymes and polynucleotides encoding them are provided. Methods to prepare jerangolid in pharmaceutically useful quantities are described, as are methods to prepare jerangolid analogs and other polyketides using the polynucleotides encoding jerangolid synthase domains or modifying enzymes.... Agent: Kosan Biosciences, Inc

20080207874 - Peptide antibiotics and methods for making same: Novel protected cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics. Intermediates are readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; but also are useful and potent against gram-positive bacteria.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080207875 - Preventive and therapeutic use of polypeptides from african swine virus as vaccines: The present invention relates to the use of selected polypeptides from African Swine virus for the prevention and therapy of African Swine infections as well as other infections, including immune deficiencies in mammals and humans.... Agent: Inhouse Co.

20080207876 - Triazines and pyrimidines as protein binding ligands: Compounds of the general formula (I): in which inter alia Q1 represents —NR1R3, —OR1 or —SR1 and Q2 represents —NR2R4, —OR2 or —SR2, and A represents the point of attachment to a support matrix, are useful as protein binding ligands when (a) at least one of R1, R2, R3 and... Agent: Nixon Peabody LLP - Patent Group

20080207877 - Modified human four helical bundle polypeptides and their uses: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080207878 - Process for separating proteins fibrinogen, factor xiii and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins: d

20080207879 - Method for the purification of recombinant blood coagulation factor ix enriched in sulfated and/or phosphorylated molecules: The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to... Agent: Baxter Healthcare Corporation

20080207880 - Reduction of the content of protein contaminents in compositions comprising a vitamin k-dependent protein of interest: The present invention relates to Vitamin K-dependent protein compositions having a very low, or negligible, content of protein contaminants. The present invention also relates to method applicable in the preparation of such Vitamin K-dependent protein compositions. Such methods may either be used alone or in sequential combination with the purpose... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080200644 - Method for inverse solid phase synthesis of peptides: P

20080200645 - Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury: The invention provides the use of a complement inhibitor in the preparation of a medicament for the treatment or prophylaxis of atherosclerosis in a subject in need of treatment by administering to the subject a therapeutically effective amount of said medicament. The complement inhibitor may be a molecule which can... Agent: Stites & Harbison, PLLC

20080200646 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Lowrie, Lando & Anastasi, LLP

20080200647 - On-resin peptide cyclization: Method of peptide synthesis, comprising the steps of a. synthesizing a peptide linked to a solid phase which peptide comprises at least one cysteine, homo- or nor-cysteine residue, which cysteine is protected in its side chain by a S-tert.butyl-sulphenyl group b. either coupling N-terminally a further amino acid having a... Agent: Nixon & Vanderhye, PC

20080200648 - Method of peptide synthesis: A novel for amidation of C-terminal carboxyl groups of peptides is devised, which methods avoids undesired epimerisation of the α-carbon of the C-terminal amino acid yielding diastereoisomeric variants of the amidated peptide.... Agent: Nixon & Vanderhye, PC

20080200649 - Method: A method for optimised refolding of a protein which method comprises selecting for the protein at least three control factors which affect refolding of the protein and at least three levels for each control factor, making a Taguchi matrix of the control factors and levels, conducting experiments as required by... Agent: Astrazeneca R&d Boston

20080200650 - Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.... Agent: Mueting, Raasch & Gebhardt, P.A.

20080200651 - Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine: The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080200654 - Anti-a33 antibody: The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant... Agent: Foley And Lardner LLP Suite 500

20080200653 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Heller Ehrman LLP

20080200652 - Novel cherkasky fusion proteins containing antibody binding proteins or the regions thereof: Disclosed are novel fusion proteins containing antibody binding regions and certain other regions. Said fusion proteins can form complexes with antibodies, which can thus be modified and be arranged three-dimensionally. Furthermore, the effect thereof can be boosted.... Agent: Alexander Cherkasky

20080200655 - Protein formulations containing sorbitol: The present invention provides a method for suppressing protein aggregation in a liquid formulation during freeze-thaw by including sorbitol in the liquid formulation. The present invention also provides methods for storing and preparing a liquid formulation containing a protein and sorbitol such that the presence of sorbitol suppresses protein aggregation... Agent: Choate, Hall & Stewart LLP/wyeth

20080200656 - Use of sucrose to suppress mannitol-induced protein aggregation: The present invention provides a method for suppressing mannitol-induced protein aggregation by providing sucrose to a liquid formulation containing a protein. The present invention also provides methods for storing and preparing a liquid formulation containing a protein and a combination of mannitol and sucrose such that the presence of sucrose... Agent: Choate, Hall & Stewart LLP/wyeth

20080200657 - Mutant of granulocyte-colony stimulating factor (g-csf) and chemically conjugated polypeptide thereof: Provided are mutants of human granulocyte-colony stimulating factor (G-CSF) designed for specific chemical conjugation, and chemical conjugates thereof for use as an adjuvant in the treatment of cancer. The present invention provides a mutant of a G-CSF in which a threonine (Thr) residue at position 133 of G-CSF comprising the... Agent: Sughrue Mion, PLLC

20080200658 - Process for the purification of il-18 binding protein: The invention relates to a process for the production of purified IL-18 binding protein (IL-18BP) from a fluid comprising affinity chromatography.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080194795 - Oxidized and maleated compounds and compositions: Oxidized and maleated compositions, such as oxidized and maleated tall oil compositions, can be prepared and used in a variety of industrial applications, including as emulsifiers and corrosion inhibitors.... Agent: Fish & Richardson P.c.

20080194796 - Methods for arbitrary peptide synthesis: Methods, apparatus, systems, computer programs and computing devices related to biologically assembling and/or synthesizing peptides and/or proteins are disclosed.... Agent: Searete Llc Clarence T. Tegreene

20080194797 - Leucine-based motif and clostridial neurotoxins: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods... Agent: Allergan, Inc.

20080194798 - Novel iminecalixarene derivatives, method for preparing the same, self-assembled monolayer prepared by using the iminecalixarene derivatives or aminocalixarene, and protein chip using the self-assembled monolayer: The present invention relates to iminecalixarene derivatives, iminecalixarene derivative monolayers prepared as a monolayer on a solid substrate by using said iminecalixarene derivatives, a protein chip substrate prepared by fixing all kinds of proteins on a chip substrate in a solution phase without any treatment, while ammonium groups on the... Agent: Howrey LLP

20080194799 - Modified chimeric polypeptides with improved pharmacokinetic properties: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides... Agent: Regeneron Pharmaceuticals, Inc

20080194800 - Human receptor proteins; related reagents and methods: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080188640 - Immunodeficiency recombinant poxvirus: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can... Agent: Robert Yoshida Sanofi Pasteur Inc.

20080188641 - Methods for detecting and inhibiting angiogenesis: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the... Agent: Townsend And Townsend And Crew, LLP

20080188642 - Process for isolating biomaterial from tissue and an isolated biomaterial extract prepared therefrom: A process for isolating a biomaterial extract from tissue is disclosed. The process comprises the step of contacting the tissue with an extracting solution so as to extract a biomaterial into solution. A solution containing the biomaterial extract is separated before being freeze-dried at a rate sufficient to enable the... Agent: Mcdermott, Will & Emery

20080188643 - Flk-1 binding protein: A protein designated flk-1bp binds the vascular endothelial cell surface receptor flk-1. Isolated DNA encoding flk-1bp is provided, along with expression vectors and transformed host cells useful in producing flk-1bp polypeptides. Antibodies that are immunoreactive with flk-1bp are generated using the polypeptides disclosed herein.... Agent: Immunex Corporation Law Department

20080188644 - Lactoferrin: A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the... Agent: Fish & Richardson PC